Fidia Farmaceutici has now a subsidiary in Russia

Fidia Farmaceutici has established a wholly owned subsidiary in Russia, further enhancing its presence in growing markets.

Fidia Pharma Russia will be instrumental in scaling up the company’s activities in the Russian market (according to IMS Health, the Russian pharma products market can become 8th in the world by 2017) and will enable the company to attend customers in the market more thoroughly and effectively, with product training courses and high-profile presentations.

The Moscow-based, Fidia Pharma Russia subsidiary was formally inaugurated on November 3rd, 2015 and today, employs 45 people, with a diversified product portfolio focusing on branded pharmaceuticals and medical devices, as well as dietary supplements, with specialization in Joint and Wound care, Women’s health, liver and ENT diseases.

The completion of this project further demonstrates Fidia’s transition into a truly global business, and strategic investment into key emerging markets, such as Russia.


Find out more about Fidia’s product portfolio:

Go to the website


Fidia Farmaceutici has a specific module dedicated to Pharmaco-Vigilance in order to promptly reporting of suspected adverse reactions. If you suspect that you have had an adverse reaction while taking one of our products or you have found defects

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint care
- ophthalmology
- active wound care
- neuroscience
- aesthetic medicine